Clinical trials


Allina Health Research is responsible for conducting clinical studies and collaborating with the community‚Äôs premier research houses to advance the treatment of our patients. We are committed to the improvement of patient care through discovery. 

Allina Health Research collaborates with various health organizations through a variety of clinical trials. With the help of these partnerships, Allina Health is able to create new avenues for treatment.

With over 600 research studies to date, our experienced researchers and collaborators take pride in bettering the medical community and enhancing population health in the communities we serve.

Current clinical studies

Breast Cancer

Sea Gen SGNTUC-025 Metastatic HER2+ Breast Cancer Study (3rd Line): Phase 2 study of tucatinib + trastuzumab deruxtecan in previously treated unresectable metastatic HER2+ breast cancer. 
Contact: Tsai/Lori 612-863-1093

Seattle Genetics SGN-LIV1A Breast Cancer Study: Phase 1 Study (Part F) of SGN-LIV1A for patients with 1st line PD-L1 low or negative locally-advanced or metastatic triple negative breast cancer.  Minneapolis, Fridley & Coon Rapids.
Contact: Tsai/Jackie 612-863-3929

Seattle Genetics SGN-LVA-002 Triple Negative Study (1st Line) : Phase 1b/2 Study of SGN-LIV1A + pembrolizumab for first-line treatment of unresectable, locally-advanced, or metastatic triple negative breast cancer (Tsai/Jackie 612-863-3929).

Merck MK-7339-009 Triple Negative Study: Open label, randomized Phase 2/3 study of olaparib + pembrolizumab vs. chemotherapy + pembrolizumab after induction of clinical benefit with first-line chemo + pembrolizumab for metastatic triple negative breast cancer.
Contact: Tsai/Jen 612-863-5501

CTMX-2009-002: Phase 2, Open-Label Study of CX-2009 as Monotherapy and in Combination with CX-072 in Advanced TNBC with 1-2 prior lines of therapy. (PI Tsai/L RN Lori 612-863-1093)

CTMX-2009-002: Phase 2, Open-Label Study of CX-2009 in Advanced HR+/HER2- breast cancer with 2-4 prior lines of therapy. (PI Tsai/L RN Lori 612-863-1093)

Hepatobiliary Cancer

P1719-SUR-Z11: A Phase 2, Open-label Study of an Immunotherapeutic Treatment, DPX-Survivac in combination with Low Dose Cyclophosphamide and Pembrolizumab in Subjects with Advanced/Recurrent HCC
(PI Squillante/ RN Jen 612-863-5501)

LAM 001-2018 ELITE Protocol: Biospecimen Collection of blood from Patients with Precancerous Liver Conditions and Patients with all stages of active disease.
Contact: Tsai/Jennifer 612-863-5501

Lung Cancer 

AZ ADRIACTIC Limited Stage SCLC: RCT of placebo-controlled consolidation treatment durvalumab or durvalumab and tremilimumab for patients with limited stage SCLC who have not progressed following concurrent chemoradiation therapy.
Contact: Tsai/Jackie 612-863-3929

AZ MERMAID 1: Phase III randomized, double-blind, study to determine the efficacy of adjuvant durvalumab/placebo + platinum-based chemotherapy in completely resected stage II-III NSCLC.
Contact: Tsai/Jackie 612-863-3929

AZ MERMAID 2: Phase III randomized, double-blind, study of durvalumab/placebo for the treatment of stage II-III NSCLC patients with minimal residual disease following surgery and curative intent therapy.
Contact: Tsai/Jackie 612-863-3929

AZ COMPEL: Phase III, randomized, double-blind, placebo-controlled study of platinum + Pemetrexed chemotherapy Plus Osimertinib/Placebo in patients with EGFRm, locally advanced or metastatic NSCLC who have progressed extracranially following first-line Osimertinib therapy.
Contact: Tsai/Stephanie 612-863-1752


AZ Mantle Cell Lymphoma (MCL) SUMMIT Registry: Registry study of patients who are initiating a novel agent for MCL to assess treatment patterns, response rates, PFS and overall survival.
Contact: Tsai/Jen 612-863-5501


BMS CA209-76K Melanoma: Phase 3, randomized, double-blind study of adjuvant immunotherapy with nivolumab versus placebo after complete resection of Stage IIB/C melanoma. Minneapolis & Fridley locations.
Contact: Amatruda/Stephanie 612-863-1752 or Lynne 763-236-5619

Castle Biosciences PERSONALize: Study to evaluate outcomes of DecisionDx Melanoma test results. Fridley, Coon Rapids & St. Paul locations.
Contact: Amatruda/Lynne 763-236-5619

BMS CA045-001:Phase 3, Randomized, Open-Label study of NKTR-214 combined with Nivolumab Versus Nivolumab in participants with previously untreated, unresectable metastatic melanoma. Minneapolis, St. Paul & Fridley locations.
Contact: Amatruda/Jen 612-863-5501 or Lynne 763-236-5619

Pancreatic Cancer

Geistlich GP-2250 1001 Pancreas Cancer Study: Phase 1/ 2 trial of GP-2250 + gemcitabine in metastatic pancreatic cancer who have progressed on FOLFIRINOX.  Minneapolis, Coon Rapids & Fridley locations.
Contact: Tsai/Jen 612-863-5501

Urothelial Cancer 

P1719-SUR-Z11: A Phase 2, Open-label Study of an Immunotherapeutic Treatment, DPX-Survivac in combination with Low Dose Cyclophosphamide and Pembrolizumab in Subjects with Advanced/Recurrent Urothelial Cancer (including urinary bladder, ureter, urethra and renal pelvis).
(PI Squillante/ RN Jen 612-863-5501)

Minneapolis Heart Institute Foundation

Learn more about the Minneapolis Heart Institute Foundation clinical trials.

Metropolitan Heart & Vascular Institute

Learn more about the Metropolitan Heart & Vascular Institute clinical trials.

United Heart & Vascular Clinic

Study name: Multicenter Imaging in Lead Extraction Study (MILES)
Study summary: The primary objectives of this registry is to correlate the amount of fibrosis as documented on Electrocardiogram (ECG) gated Computed Tomography (CT) scans with ease of advancing sheaths over the leads through the SVC zone during lead extraction.
Contact: Katie Bisch,, 651-241-2913
More information:

Study name: Reducing Lung Congestion Symptoms in Advanced Heart Failure (RELIEVE-HF)
Study summary: The objective of the RELIEVE-HF study is to provide reasonable assurance of safety and effectiveness of the V-Wave Interatrial Shunt System by improving meaningful clinical outcomes in patients with New York Heart Association (NYHA) functional class III or ambulatory class IV heart failure (HF), irrespective of left ventricular ejection fraction, who at baseline are treated with guideline-directed drug and device therapies.
Contact: Katie Schwister,, 651-241-2816
More information:

Study name: The DES BTK Vascular Stent System vs PTA in Subjects With Critical Limb Ischemia (SAVAL)
Study summary: Two phased global, prospective, multicenter clinical trial designed to demonstrate a superior patency rate and acceptable safety in below the knee arteries with lesions treated with the DES BTK Vascular Stent System vs. percutaneous transluminal angioplasty (PTA).
Contact: Nikki Gernes,, 651-241-2216
More information:

Study name: Stimulation Of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy in Non-Responders and Previously Untreatable Patients (SOLVE CRT)
Study summary: This study is a prospective, multi-center, randomized, controlled, double blinded, pivotal trial to study the safety and efficacy of the WiSE-CRT System for Cardiac Re-synchronization Therapy.
Contact: Nikki Gernes,, 651-241-2216
More information:

Study name: Narrow QRS HF Patients Assessed by ECG Belt
Study summary: The purpose of this study is to quantitate electrical dyssynchrony in heart failure (HF) patients with a narrow QRS complexes (≤ 130 ms) using the ECG Belt. This is a pilot study that is designed to provide data that can be used in designing and implementing a prospective study of cardiac resynchronization therapy (CRT) in narrow QRS patients selected and optimized using the ECG Belt.
Contact: Chris Brown,, 651-241-2806
More information:

Study name: ECG Belt vs. Echocardiographic Optimization of CRT
Study summary: Cardiac resynchronization therapy (CRT) has been a valuable intervention for patients with systolic heart failure for over 15 years. Despite years of research, there is a still a 25-40% non-responder rate depending on the outcomes measured. CRT optimization is a term used to describe the act of individualizing the therapy (CRT programming) for an individual patient. This is not often performed, but when it is, echocardiography is utilized. Recent work of body surface mapping using a novel system called the ECG Belt has shown a relationship between measures of electrical dyssynchrony and acute and chronic heart pumping function. This study will compare outcomes of patients randomized to either echocardiographic or ECG Belt optimization of CRT devices.
Contact: Chris Brown,, 651-241-2806
More information:

No current clinical trials.

Study summary: This Phase 2b study will evaluate the safety, tolerability, and immunogenicity of an RSV vaccine in pregnant participants who receive either one of 2 dose levels of the vaccine, formulated with or without aluminum hydroxide, or placebo, and investigate safety and characteristics of antibodies in their infants.
Contact: Adrienne Baranauskas,, 612-863-0999; Jessie Whelan,, 612-863-7046
More information:
Study name: AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke (ARCADIA)
Study summary: Primary: To test the hypothesis that apixaban is superior to aspirin for the prevention of recurrent stroke in patients with cryptogenic ischemic stroke and atrial cardiopathy. Secondary: To test the hypothesis that the relative efficacy of apixaban over aspirin increases with the severity of atrial cardiopathy.
Contact: Kayla Stiernagle,
More information:

Study name: Sleep for Stoke Management and Recovery Trial (Sleep SMART)
Study summary: The purpose of this study is to determine whether treatment of obstructive sleep apnea (OSA) with positive airway pressure starting shortly after acute ischemic stroke or high risk TIA (1) reduces recurrent stroke, acute coronary syndrome, and all-cause mortality 6 months after the event, and (2) improves stroke outcomes at 3 months in patients who experienced an ischemic stroke.  
Contact: Bridget Ho,, 651-241-7321
More information:

Study name: Multi-arm Optimization of Stroke Thrombolysis (MOST) 
Study summary: The primary efficacy objective of the MOST trial is to determine if argatroban (100µg/kg bolus followed by 3µg/kg per minute for 12 hours) or eptifibatide (135µg/kg bolus followed by 0.75µg/kg/min infusion for two hours) results in improved 90-day modified Rankin scores (mRS) as compared with placebo in acute ischemic stroke (AIS) patients treated with 0.9mg/kg IV rt-PA within three hours of symptom onset. Patients may also receive endovascular thrombectomy (ET) per usual care. Time of onset is defined as the last time the patient was last known to be well.
Contact: Nilanjana Banerji,, 612-863-3042
More information:

Study name: FILtration of Subarachnoid Hemorrhage Via SpinaL CAtheteR Extension (PILLAR-XT)
Study summary: The objective of this study is to further demonstrate safety and characterize effectiveness of the Neurapheresis™ System (extracorporeal system and catheter) to remove red blood cells (RBCs) and lysed blood by-products from hemorrhagic cerebrospinal fluid (CSF) following aneurysmal subarachnoid hemorrhage (aSAH).
Contact: Nilanjana Banerji,, 612-863-3042
More information:

Study name: Validation of Readiband™ Actigraph and Associated Sleep/Wake Classification Algorithms  
Study summary: This pilot study will assess feasibility and to obtain initial estimates of efficacy of Sleep Activity and Task Effectiveness (SAFTE) model, which can accurately estimate the impact of scheduling factors and sleep history on both safety and productivity. The SAFTE model will be used to assess cancer-related fatigue and study potential associations of change in sleep patterns to tumor recurrence in patients with high grade glioma. Data will be collected using the Readiband™ Sleep Tracker ( The Readiband device captures high-resolution sleep data, validated against the clinical gold standard of polysomnography with 92% accuracy. Sleep data is transmitted to the cloud automatically for SAFTE Fatigue Model analysis. We will correlate clinical progression data obtained from the patient's electronic medical record with SAFTE data.
Contact: Amy Ellenberger,, 612-863-3452
More information:

Study name: A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy (WIZARD 201G)
Study summary: This is a randomized, active-controlled, multicenter, open-label, parallel groups, Phase 2 study of DSP-7888 Dosing Emulsion plus Bevacizumab versus Bevacizumab alone in patients with recurrent or progressive glioblastoma multiforme (GBM) following treatment with first line therapy consisting of surgery and radiation with or without chemotherapy. 
Contact: Nilanjana Banerji,, 612-863-3042
More information:

Study name: Effect of TTFields (150 kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-10 Brain Metastases Following Radiosurgery (METIS)
Study summary: The study is a prospective, randomized controlled phase III trial, to test the efficacy, safety and neurocognitive outcomes of advanced NSCLC patients, following stereotactic radiosurgery (SRS) for 1-10 brain metastases, treated with NovoTTF-100M compared to supportive treatment alone. The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.
Contact: Meghan Hultman,, 612-863-3308
More information:

Study name: Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects (INTACT)
Study summary: Open-label, randomized, controlled, phase 3 safety and efficacy registration trial.  Subjects will be randomized at baseline to the standard of care for first-line treatment of glioblastoma plus Trans Sodium Crocetinate (TSC) or the standard of care.
The standard of care for GBM will consist of temozolomide plus radiation therapy for 6 weeks followed by 28 days of rest followed by 6 cycles of post-radiation temozolomide treatment
More information:

Study name: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE) 
Study summary: Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM. 
Contact: Nilanjana Banerji,, 612-863-3042
More information:
No current clinical trials.

Thank you for your interest in our studies. All recruitment for studies is currently suspended due to COVID-19. Please check back for updates.

No current clinical trials.

Study name: Tornier Shoulder Outcomes Study to Examine Safety and Functional Outcomes in Shoulder Arthroplasty and Fracture Patients  
Study summary: The Tornier Shoulder Outcomes Study is designed to collect safety and efficacy data on designated commercially available Tornier Shoulder repair products. In addition, this study will provide performance data for use in education, marketing materials, peer-reviewed publications and support research and development of future products
Contact: Ned Tervola,, 952-914-8594; Katie Sjostrom,
More information:

Contact us

Your privacy is important to us. We will not reveal personally identifiable information about you. We do not sell or otherwise share our email lists with others. Read our complete privacy policy.